Annual report [Section 13 and 15(d), not S-K Item 405]

SEGMENT INFORMATION (Details)

v3.25.4
SEGMENT INFORMATION (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]      
Total revenues $ 294,282 $ 179,278 $ 116,882
Less:      
Cost of product sales 19,621 18,647 7,110
(Benefit from) provision for income taxes (245,197) 881 0
Net income (loss) 367,024 17,485 (25,091)
Single reportable segment      
Segment Reporting Information [Line Items]      
Total revenues 294,282 179,278 116,882
Less:      
Employee related expenses 75,314 69,807 63,429
Commercial related expenses 25,898 26,996 24,310
Cost of product sales 19,621 18,647 7,110
Consultants and third-party services 15,146 15,532 17,942
Outside clinical trial related expenses 18,307 10,978 9,694
Other segment items 14,530 13,126 14,888
Interest expense, net 3,639 5,826 4,600
(Benefit from) provision for income taxes (245,197) 881 0
Net income (loss) $ 367,024 $ 17,485 $ (25,091)